Saturday, March 15, 2025
4.4 C
London
HomeFinTechMGC Pharmaceuticals: Completes COVID-19 phase two test

MGC Pharmaceuticals: Completes COVID-19 phase two test

Date:

ABN AMRO-Owned Neobroker Fined $1.6M for Paying Finfluencers

A Significant Penalty in the Financial Industry Highlights Regulatory...

AvidXchange Explores Potential Sale Amid Market Changes

What Investors Need to Know About AvidXchange's Strategic ShiftHighlights:...

Raisin Expands Its Offerings by Launching in Finland

Discover how Raisin is transforming the financial landscape in...
  • MGC Pharmaceuticals (MXC) has completed its COVID-19 phase two clinical trial
  • The trial saw 50 virus-infected patients treated with MGC’s anti-inflammatory treatment, ArtemiC
  • Then the aim of the trial was to test the efficacy and safety of the treatment and evaluate the patient’s recovery rates
  • Results of the trial will reported in the next month following an independent technical review and statistical validation of the trial data
  • The second wave of the pandemic is again putting increased pressure on a number of healthcare systems around the world
  • On the market this afternoon, MGC is up 10 per cent and is trading for 2.2 cents per share

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories